biosimilars expected to take toll on amgen
TRANSCRIPT
Biosimilars Expected to Take Toll on AmgenBiosimilar competition to multiple drugs is expected to reduce Amgens sales by
nearly US$ 9 Billion during 2013-2020
IMARC Group has recently released a new study suggesting that biosimilars will erode a significant portion of Amgens sales during 2013-2020. According to the report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” four products from Amgen - Enbrel (Ethanercept), Epogen (Epoetin Alfa), Neupogen (Filgrastim) and Neulasta (Pegfilgrastim) are expected to face biosimilar competition during 2013-2020. The study that has done a robust analysis on 21 biopharmaceuticals facing biosimilar competition expects the combined sales of Amgens four drugs to decline by US$ 9 Billion during 2011-2020.
IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.
Key Aspects Analyzed:
Evaluating the Current Market Landscape of Biosimilars:
Identification of currently marketed biosimilars and their historical performance
Identifying the reasons for the slow uptake of currently marketed biosimilars
Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilar
Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:
Analyzing historical time series data on price, volume and sales erosion in the US & Europe
Analyzing previous models and assumptions on price and volume erosion caused by biosimilars
Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics
Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classes
Evaluating the Market Potential of Biosimilars Across Various Molecules:
Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).
Focus of the Analysis for Each Molecule:
Historical background and overview Historical brand sales Patent position Competing products Biosimilars in pipeline Brand and biosimilar sales forecast
Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency
Focus of the Analysis for Each Indication:
Historical brand sales Brand and biosimilar sales forecasts Indication wise breakup of molecules
Evaluating the Biosimilar Competitive Landscape:
Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars
Identifying biosimilar manufacturers and their pipelines
To obtain the complete report, please contact:
Asia: [email protected]
Phone: +91-120-425-6531
Europe, Middle East & Africa: [email protected]
Phone: +44-702-409-7331
North & South America: [email protected]
Phone: +1-631-791-1145
To know more please visit: http://www.imarcgroup.com/biosimilarfollow-on-biologics-market-report-forecast-a-focus-on-the-us-2011-2020/
Keywords
Biosimilar market, biosimilar industry, biogenerics market, us biosimilar market, biosimilar
monoclonal antibodies , follow-on biologics market,